Get the Stockscreener App
0.65
0.18%
0.0012
Xilio Therapeutics Inc stock is traded at $0.65, with a volume of 663.50K.
It is up +0.18% in the last 24 hours and down -6.20% over the past month.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).
See More
Previous Close:
$0.6488
Open:
$0.64
24h Volume:
663.50K
Relative Volume:
0.59
Market Cap:
$33.66M
Revenue:
-
Net Income/Loss:
$-81.22M
P/E Ratio:
-0.2196
EPS:
-2.96
Net Cash Flow:
$-74.41M
1W Performance:
-6.70%
1M Performance:
-6.20%
6M Performance:
-7.80%
1Y Performance:
-31.58%
1-Day Range:
$0.615
$0.6568
1-Week Range:
$0.615
$0.719
52-Week Range:
$0.615
$1.70
Xilio Therapeutics Inc Stock (XLO) Company Profile
Name
Xilio Therapeutics Inc
Sector
Industry
Phone
617-833-1027
Address
828 WINTER STREET, WALTHAM
Compare XLO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XLO
Xilio Therapeutics Inc
|
0.65 | 33.60M | 0 | -81.22M | -74.41M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-21-22 | Initiated | Chardan Capital Markets | Buy |
| Jan-10-22 | Initiated | H.C. Wainwright | Buy |
| Nov-16-21 | Initiated | Cowen | Outperform |
| Nov-16-21 | Initiated | Guggenheim | Buy |
| Nov-16-21 | Initiated | Morgan Stanley | Overweight |
| Nov-16-21 | Initiated | Raymond James | Outperform |
View All
Xilio Therapeutics Inc Stock (XLO) Latest News
What institutional investors are buying Xilio Therapeutics Inc. stockUnlock powerful investment tools for free - jammulinksnews.com
What makes Xilio Therapeutics Inc. stock price move sharplyAchieve consistent profits with smart trading - jammulinksnews.com
When is Xilio Therapeutics Inc. stock expected to show significant growthBuild wealth faster with expert stock picks - jammulinksnews.com
Is Xilio Therapeutics Inc. a growth stock or a value stockAchieve rapid wealth accumulation through smart investing - jammulinksnews.com
Why is Xilio Therapeutics Inc. stock attracting strong analyst attentionAccelerated wealth expansion - jammulinksnews.com
What are Xilio Therapeutics Inc. company’s key revenue driversMaximize gains with proven stock analysis - jammulinksnews.com
What is Xilio Therapeutics Inc. company’s growth strategyIdentify winners with top-tier analysis - jammulinksnews.com
What are the latest earnings results for Xilio Therapeutics Inc.Maximize returns with effective portfolio management - jammulinksnews.com
Xilio Therapeutics Inc. Stock Analysis and ForecastNavigate the market with precision tools - jammulinksnews.com
MACD Cross Could Confirm Trend in Xilio Therapeutics Inc.Alpha Driven Watchlist With Alerts Published - metal.it
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
What is the risk reward ratio of investing in Xilio Therapeutics Inc. stockMarket Forecast Data Feed From AI Tools - jammulinksnews.com
Xilio Therapeutics Awards $87K Worth of Stock Options in Key Employee Inducement Plan - Stock Titan
Why Xilio Therapeutics Inc. stock attracts strong analyst attentionVolume Based Entry Signal Outlook - beatles.ru
Will Xilio Therapeutics Inc. rebound enough to break evenRisk Adjusted Technical Entry Plan Gains Followers - metal.it
Breakout Traders Target Xilio Therapeutics Inc. on Recovery SetupCapital Efficiency Optimized Stock Alerts Reviewed - metal.it
Xilio Therapeutics Inc. Forms Bullish Flag — Upside AheadReal-Time Market Sentiment Tracking Gains Momentum - metal.it
Bristol Myers Squibb and Bain Capital Form New Immunology Company - MarketWatch
Does Xilio Therapeutics Inc. stock perform well during market downturnsTremendous growth opportunities - jammulinksnews.com
How does Xilio Therapeutics Inc. generate profit in a changing economyHigh-yield investments - jammulinksnews.com
Published on: 2025-07-28 02:43:54 - jammulinksnews.com
How Resilient Is Xilio Therapeutics Inc. Stock During Economic DownturnsMassive Upside Selection - Newser
What analysts say about Xilio Therapeutics Inc. stockHigh-yield capital appreciation - PrintWeekIndia
What risks could impact Xilio Therapeutics Inc. stock performanceDynamic investment growth - jammulinksnews.com
Does Xilio Therapeutics Inc. stock pay reliable dividendsRecord-breaking gains - jammulinksnews.com
What makes Xilio Therapeutics Inc. stock attractive to long term investorsRapid wealth accumulation - jammulinksnews.com
Is Xilio Therapeutics Inc. a good long term investmentOverwhelming profit margins - jammulinksnews.com
What drives Xilio Therapeutics Inc. stock priceHigh-return market picks - jammulinksnews.com
Xilio Therapeutics Inc Stock (XLO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):